Publications-Periodical Articles

Article View/Open

Publication Export

Google ScholarTM

NCCU Library

Citation Infomation

  • Loading...
    SCOPUS®0

Related Publications in TAIR

TitleTaiwan`s Efforts to Recreate Remdesivir
Creator陳秉訓
Chen, Ping-Hsun
Contributor科管智財所
Key WordsRemdesivir;Taiwan;patent;COVID-19;compulsory licensing
Date2021-06
Date Issued11-Apr-2022 14:32:38 (UTC+8)
SummaryThis article reports Taiwan`s efforts to replicate remdesivir to prepare for combating COVID-19. There were two state-funded institutions and two private pharmaceutical companies working on remdesivir synthesis. They all claimed to successfully complete remdesivir of a high purity. But, since Gilead Sciences, Inc. has patented remdesivir in Taiwan, the Taiwan Government needs to initiate compulsory licensing under the Patent Act to start large-scale manufacturing of remdesivir within its territory.
RelationBiotechnology Law Report, Vol.40, No.3, pp.174-183
Typearticle
DOI http://doi.org/10.1089/blr.2021.29227.phc
dc.contributor 科管智財所
dc.creator (作者) 陳秉訓
dc.creator (作者) Chen, Ping-Hsun
dc.date (日期) 2021-06
dc.date.accessioned 11-Apr-2022 14:32:38 (UTC+8)-
dc.date.available 11-Apr-2022 14:32:38 (UTC+8)-
dc.date.issued (上傳時間) 11-Apr-2022 14:32:38 (UTC+8)-
dc.identifier.uri (URI) http://nccur.lib.nccu.edu.tw/handle/140.119/139805-
dc.description.abstract (摘要) This article reports Taiwan`s efforts to replicate remdesivir to prepare for combating COVID-19. There were two state-funded institutions and two private pharmaceutical companies working on remdesivir synthesis. They all claimed to successfully complete remdesivir of a high purity. But, since Gilead Sciences, Inc. has patented remdesivir in Taiwan, the Taiwan Government needs to initiate compulsory licensing under the Patent Act to start large-scale manufacturing of remdesivir within its territory.
dc.format.extent 230493 bytes-
dc.format.mimetype application/pdf-
dc.relation (關聯) Biotechnology Law Report, Vol.40, No.3, pp.174-183
dc.subject (關鍵詞) Remdesivir;Taiwan;patent;COVID-19;compulsory licensing
dc.title (題名) Taiwan`s Efforts to Recreate Remdesivir
dc.type (資料類型) article
dc.identifier.doi (DOI) 10.1089/blr.2021.29227.phc
dc.doi.uri (DOI) http://doi.org/10.1089/blr.2021.29227.phc